Alumni Ventures Group
Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, with offices across North America. It provides access to venture investing for individual accredited investors, particularly alumni networks, by offering diversified portfolios of venture opportunities and allowing members to invest alongside fellow alumni in ventures led by peers. The firm backs early-stage and later-stage opportunities across technology, consumer, healthcare, financial services, and other sectors, with a sector- and geography-agnostic approach. It typically invests between $10,000 and $3 million per deal and emphasizes the involvement of alumni connections and an institutional lead investor in opportunities. Alumni Ventures also offers focused funds to broaden participation, enabling accredited investors to access venture portfolios diversified by type, sector, stage, and geography. The model aims to democratize access to venture capital while maintaining rigorous selection standards through alumni networks.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Genetics
GC Therapeutics
Series A in 2024
GC Therapeutics employs synthetic biology to transform patient-derived stem cells into diverse cell types efficiently and at scale. The company has validated its technology across multiple applications, creating SuperCells™ tailored for specific conditions. Originally developed in Professor George Church's lab at Harvard Medical School, GC Therapeutics is dedicated to bringing this innovative method to patients.
Q Bio
Venture Round in 2024
Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.
caVos biotherapeutics
Seed Round in 2024
An emerging genomic and data science company, developing novel drugs based on naturally occurring resistance mechanisms
ParcelBio
Seed Round in 2024
ParcelBio is a biotechnology company specializing in the development of a novel, programmable method for safely and precisely delivering messenger RNA (mRNA) to diverse cell types within the body. Their technology aims to create targeted, potent, and durable RNA therapeutics, with the potential to treat a wide range of diseases, including cancer, genetic disorders, and infectious diseases.
HelixNano
Series A in 2024
HelixNano is a biotechnology startup that employs artificial intelligence and synthetic biology to develop innovative treatments for genetic diseases. Founded with backing from Y Combinator and venture capitalists, the company initially focused on creating cancer vaccines over two years. Currently, HelixNano is adapting its technology to combat COVID-19, aiming to produce precise and safe vaccine candidates. Its long-term goal is to develop a universal coronavirus vaccine that protects against future outbreaks.
Earli
Series A in 2024
Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.
Anthology
Pre Seed Round in 2023
Anthology is an evolution company that generates diverse genomes to scale and digitalize biomanufacturing.
Ossium Health
Series C in 2023
Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.
3X Genetics
Pre Seed Round in 2023
3X Genetics is a company focused on developing medical screening solutions aimed at identifying genetic disorders, particularly in infants and children. The company has created innovative technologies that allow for proactive screening of the population for conditions such as myotonic dystrophy and other trinucleotide repeat issues associated with progressive muscle weakness. By enabling healthcare professionals to detect these genetic disorders early, 3X Genetics plays a crucial role in preventing the birth of children affected by serious genetic diseases.
Nanopath
Series A in 2022
Nanopath is a molecular diagnostics company that develops innovative platforms for rapid disease diagnosis. Its technology enables point-of-care testing, eliminating the need for nucleic acid amplification and supporting multiplexed detection. This allows patients and healthcare providers to access accurate diagnostic results within standard office visits, improving healthcare outcomes.
Legacy
Series B in 2022
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
American Gene Technologies International
Series D in 2022
American Gene Technologies International is a gene and cell therapeutics company developing a lentiviral platform for broad applications across infectious diseases, immuno-oncology, monogenic disorders, and regenerative medicine. It pursues HIV cure strategies, including a lead candidate for functional cure, and an immuno-oncology approach that stimulates gamma-delta T cells to target solid tumors. The company also develops a therapeutic approach for Phenylketonuria by expressing phenylalanine hydroxylase, using proprietary viral vector and gene therapy technologies. Founded in 2007 and based in Rockville, Maryland, AGT focuses on translating its platform into therapies that aim to cure diseases rather than merely treat them.
Satellite Bio
Series A in 2022
Satellite Bio develops cell therapies and regenerative medicine approaches, spanning cell biology, tissue engineering, and synthetic biology. The company focuses on proprietary, off-the-shelf implantable satellite organs that function as living therapeutic systems to replace or augment critical organ functions in patients with serious diseases, enabling medical professionals to address conditions arising from genetic and environmental factors. Its platform supports the development of modular, scalable therapies aimed at treating complex diseases and transforming patient outcomes.
Verge Genomics
Series B in 2021
Verge Genomics is a biotechnology company that uses artificial intelligence and machine learning to accelerate drug discovery for neurodegenerative diseases. The company is founded by experts in machine learning and neuroscience drug development who believe advances in computational genomics can reveal new targets and therapies. Verge Genomics' platform analyzes datasets of any size to identify targets and predict effective drugs, with the aim of delivering treatments that improve patient outcomes while reducing the cost and duration of pharmaceutical development.
GRO Biosciences
Series A in 2021
GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.
miRecule
Venture Round in 2021
miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.
Mendel
Seed Round in 2021
Mendel Biotechnology, Inc. is a plant biotechnology company based in Hayward, California, focused on developing genetic and chemical solutions for various agricultural markets. Founded in 1997, the company specializes in enhancing agricultural productivity through innovations in biofuel feedstocks, yield enhancement, drought and freezing tolerance, disease resistance, nutrient use efficiency, and cold germination. Mendel has established strategic partnerships with notable organizations in the industry, including Monsanto Corporation, BP, and Bayer CropScience. Its operations extend across the United States, Europe, and China, reflecting a commitment to advancing agricultural technology and sustainability.
InteRNA Technologies
Series B in 2021
InteRNA Technologies B.V. is a biotechnology company focused on developing microRNA (miRNA)-based therapeutics for cancer treatment. Founded in 2006 and headquartered in Nijmegen, the Netherlands, with a research and development center in Utrecht, the company leverages its proprietary technology to discover and validate miRNA sequences that can target multiple signaling pathways involved in cancer initiation, progression, and metastasis. By addressing previously undruggable targets, InteRNA aims to enhance the efficacy of existing cancer therapies and reduce the development of drug resistance. The company employs advanced bioinformatics and massively parallel sequencing techniques to analyze miRNA functions, paving the way for innovative treatment options in oncology.
Generate Biomedicines
Venture Round in 2020
Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.
Mission Bio
Venture Round in 2020
Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.
Excision BioTherapeutics
Venture Round in 2019
Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.
miRecule
Venture Round in 2019
miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.
Motif
Series A in 2019
Motif FoodWorks, Inc. is a bio-organism engineering company based in Boston, Massachusetts, that specializes in developing innovative food ingredients. The company focuses on producing animal-free proteins, including meat alternatives and dairy-free proteins, catering to the growing demand for plant-based food solutions. By utilizing fermentation technology, Motif creates essential proteins and nutrients that enhance both nutrition and flavor in food products. The company collaborates with chefs, health experts, and food innovators to develop new ingredient solutions aimed at transforming the food industry and promoting sustainability. Established in 2018 and originally known as Motif Ingredients, Motif FoodWorks rebranded in 2019 to reflect its commitment to advancing the next generation of healthy and plant-based foods.
Legacy
Seed Round in 2019
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
Seed Health
Seed Round in 2019
Seed Health is a biotechnology company focused on therapeutics, consumer health innovations, and environmental solutions grounded in microbial sciences. It collaborates with academic researchers to advance discoveries in microbiology and develops health supplements that employ live biotherapeutics, combining probiotics and prebiotics to support digestive health, skin health, heart health, and micronutrient synthesis.
StemoniX
Series B in 2019
StemoniX Inc. is a biotechnology company that specializes in stem cell technologies aimed at advancing drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX offers a proprietary platform that facilitates the creation and scaling of human tissue derived from stem cells. This platform supports the 3-D printing of living cells for various applications, including research into heart disease, dementia, breast cancer, autism, and ALS. By operationalizing human-induced pluripotent stem cell (iPSC) disease models at scale, StemoniX enhances the efficiency of neurotoxicity research and drug screening, enabling scientists to conduct more effective studies with improved outcomes.
Clear Labs
Series B in 2018
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
American Gene Technologies International
Series D in 2018
American Gene Technologies International is a gene and cell therapeutics company developing a lentiviral platform for broad applications across infectious diseases, immuno-oncology, monogenic disorders, and regenerative medicine. It pursues HIV cure strategies, including a lead candidate for functional cure, and an immuno-oncology approach that stimulates gamma-delta T cells to target solid tumors. The company also develops a therapeutic approach for Phenylketonuria by expressing phenylalanine hydroxylase, using proprietary viral vector and gene therapy technologies. Founded in 2007 and based in Rockville, Maryland, AGT focuses on translating its platform into therapies that aim to cure diseases rather than merely treat them.
Exicure
Venture Round in 2017
Exicure, founded in 2011 and headquartered in Chicago, Illinois, is a clinical-stage biotechnology company specializing in the development of therapeutics using its proprietary spherical nucleic acid (SNA) technology. Its pipeline includes AST-008 for advanced solid tumors, XCUR-FXN for Friedreich’s ataxia, and XCUR17 targeting interleukin 17 receptor alpha. Exicure has collaborations with Allergan Pharmaceuticals International Limited and DERMELIX, LLC.
Clear Labs
Series B in 2016
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.